The observed beneficial effects of prolonged and specific targeting of CSF1R, with the orally available inhibitor GW2580, provide a proof of target engagement and efficacy in a model of Alzheimer’s disease-like pathology. This evidence concerns the gene CSF1R and early-onset autosomal dominant Alzheimer disease.